The Mitsubishi Tanabe Pharma Group is united in its efforts to practice and promote compliance with the Mitsubishi Chemical Group (the MCG Group) based on the "One Company, One Team" system.
For details, see the Mitsubishi Chemical Group Corporation (MCG) website.
Compliance
https://www.mcgc.com/english/group/compliance.html

After factoring in the gravity of the Medway Issue and the related quality control problems, (a violation of the Pharmaceutical Affairs Act and GMP ministerial ordinance), and recognizing the need to prevent any further incidents of misconduct, the Mitsubishi Tanabe Pharma Group has introduced an annual Corporate Behavior Charter Day, which offers employees the opportunity to review the Group’s Charter and reflect on their individual conduct.

In fiscal 2022, we invited an outside lecturer for another “Compliance Lecture” held remotely, which focused on the subject of “Future-orientation—Establishing compliance by seeking to attain better things.” The lecture was well-attended, with a lively question and answer session on the day, and also offered for on-demand viewing, where it has been viewed by many employees.

Compliance meetings are held annually at all worksites in Japan, focusing on exchanges of opinions, employees read the Compliance Guidebook together, and sign pledges in which they vow to conduct themselves in accordance with the Corporate Behavior Charter and the Compliance Guidebook. We also held compliance meetings at overseas Group companies by including local content in the corresponding content used in Japan.

The MCG Group has established a section on “Respecting Human Rights” in its Charter of Corporate Behavior. This makes a clear declaration that we will respect each other’s human rights, and work to create safe, comfortable working environments. The Compliance Guidebook, which can be viewed on the corporate intranet by all employees of the domestic Group, states clearly that the Group will not tolerate acts that violate human rights or prevent people from exercising their abilities, such as discrimination or harassment, or the use of power to force subordinate employees to engage in excessive work (sexual harassment, power harassment, etc.)

Additionally, in November 2022, the Group released a “Message on Prohibition of Harassment” under the name of the manager of the Japan Human Resources Department, directed to all employees of the company’s domestic Group. This message was a clear statement of the company’s stance of prohibiting harassment. Moreover, the “Harassment Prevention Guidebook” released in 2018 was revised in January 2023, with the addition of the aforementioned “Message on Prohibition of Harassment,” and other content enhanced and restated.

We believe that eliminating harassment will result in the creation of comfortable workplaces, and in turn lead to the vitalization and success of the corporate group.

Mitsubishi Tanabe Pharma is committed to protecting its customers' personal information. In keeping with its strong sense of responsibility regarding this subject, the Company has released its Privacy Policy: Personal Information Protection Policy to the public. Toward this end, the Company uses only fair and reasonable methods to collect customers' personal information and utilizes this information only to the extent necessary to achieve the permitted purpose. In addition to this fundamental approach, it has taken the following initiatives with regard to the handling of personal information.